antitumor activity. Jahrestagung der American Association for Cancer
Research (AACR) 2011, Abstract 1347; Cancer Research 2011, 71 (8
Supplement)
7. ClinicalTrials.gov-Identifier: NCT03250299
8. ClinicalTrials.gov-Identifier: NCT02895360
9. A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule
targeting agent BAL101553 in combination with radiotherapy in
treatment-refractory tumor models. Radiotherapy Oncology 2017 (124),
433-438
10. G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel
tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and
ovarian cancer variants selected for resistance to taxanes. Jahrestagung
der American Association for Cancer Research (AACR) 2010, Abstract 4412;
Cancer Research 2010, 70 (8 Supplement)
11. F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of
BAL27862): A unique microtubule destabilizer active against drug
refractory breast cancers alone and in combination with trastuzumab.
Jahrestagung der American Association for Cancer Research (AACR) 2014,
Abstract 831; Cancer Research 2014, 74 (19 Supplement)
12. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique
microtubule-targeted agent with a potential for the treatment of human
brain tumors. AACR-NCI-EORTC-Konferenz 2009, Abstract C233; Molecular
Cancer Therapeutics 2009, 8 (12 Supplement)
13. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding
'tumor checkpoint controller' BAL101553 has anti-cancer activity alone
and in combination treatments across a panel of GBM patient-derived
xenografts. Jahrestagung der American Association for Cancer Research
(AACR) 2016, Abstract 4781; Cancer Research 2016, 76 (14 Supplement)
14. A. E. Prota, F. Danel, F. Bachmann et al. The novel
microtubule-destabilizing drug BAL27862 binds to the colchicine site of
tubulin with distinct effects on microtubule organization. Journal of
Molecular Biology 2014 (426), 1848-1860
15. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the
spindle assembly checkpoint is required for anticancer activity.
Jahrestagung der American Association for Cancer Research (AACR) 2015,
Abstract 3789; Cancer Research 2015, 75 (15 Supplement)
Anhang
-- Pressemitteilung (PDF)
https://ml-eu.globenewswire.com/Resource/Download/ab1a57b7-9c28-4b82-8d3d-f90656dfdc6a
(END) Dow Jones Newswires
June 07, 2021 01:15 ET (05:15 GMT)